Yanming Wu

Yanming Wu

Auto-generated profile, based on publicly available information

Yanming Wu

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YWYanming Wu
Yanming Wu
ZZZhao Zhang
Zhao Zhang
MCMauro E. Cenciarini
Mauro E. Cenciarini
CPCecilia J. Proietti
Cecilia J. Proietti
MAMatias Amasino
Matias Amasino
KXKexin Xu
Kexin Xu
Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master transcription factor, its cofactor, and an epigenetic regulator. The oncogenic histone methyltransferase EZH2 conferred tamoxifen resistance by silencing the expression of the estrogen receptor α (ERα) cofactor GREB1. In clinical specimens, induction of DNA methylation of a particular CpG-enriched region at the GREB1 promoter negatively correlated with GREB1 levels and cell sensitivity to endocrine agents. GREB1 also ensured proper cellular reactions to different ligands by recruiting distinct sets of ERα cofactors to cis-regulatory elements, which explains the contradictory biological effects of GREB1 on breast cancer cell growth in response to estrogen or antiestrogen. In refractory cells, EZH2-dependent repression of GREB1 triggered chromatin reallocation of ERα coregulators, converting the antiestrogen into an agonist. In clinical specimens from patients receiving adjuvant tamoxifen treatment, expression levels of EZH2 and GREB1 were correlated negatively, and taken together better predicted patient responses to endocrine therapy. Overall, our work suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program. Significance: This study suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program defined within. Cancer Res; 78(3); 671–84. ©2017 AACR.

23 March 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LJLinyan Jia
Linyan Jia
XZXinyao Zhou
Xinyao Zhou
XHXiaojie Huang
Xiaojie Huang
XXXianghong Xu
Xianghong Xu
YJYuanhui Jia
Yuanhui Jia
KWKai Wang
Kai Wang
We investigated the role of exosomes derived from maternal and umbilical cord blood in the regulation of angiogenesis. We report here that both maternal exosomes (MEs) and umbilical exosomes (UEs) significantly enhance HUVEC proliferation, migration, and tube formation. Importantly, ME‐treated HUVECs (MEXs) displayed significantly increased migration, but not proliferation or tube formation, compared with UE‐treated HUVECs (UEXs). We found that the expression of a subset of migration‐related microRNAs (miRNAs), including miR‐210‐3p, miR‐376c‐3p, miR‐151a‐5p, miR‐296‐5p, miR‐122‐5p , and miR‐550a‐5p , among others, were significantly increased or decreased in UEs, and this altered expression was likely correlated with the differential regulation of HUVEC migration. We also found that the mRNA expression of hepatocyte growth factor (HGF) was up‐regulated in MEXs and UEXs and, moreover, that inhibiting HGF partially abolished the enhanced cell migration induced by UEs. Our results suggest that both MEs and UEs greatly enhanced endothelial cell (EC) functions and differentially regulated EC migration, which was mostly attributed to the different expression profiles of exosomal miRNA. These findings highlight the importance of exosomes in the regulation of angiogenesis during pregnancy. Exosomal miRNAs, in particular, may be of great significance for the regulation of angiogenesis in maintaining normal pregnancy.—Jia, L., Zhou, X., Huang, X., Xu, X., Jia, Y., Wu, Y., Yao, J., Wu, Y., Wang, K. Maternal and umbilical cord serum‐derived exosomes enhance endothelial cell proliferation and migration. FASEB J . 32, 453–4543 (2018). www.fasebj.org

27 June 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JLJingWei Lu
JingWei Lu
TPTerra-Dawn Plank
Terra-Dawn Plank
FSFang Su
Fang Su
XSXiuJuan Shi
XiuJuan Shi
CLChen Liu
Chen Liu
YLYanJun Lu
YanJun Lu
Inflammatory myofibroblastic tumors (IMTs) are characterized by myofibroblast proliferation and an inflammatory cell infiltrate. Little is known about the molecular pathways that precipitate IMT formation. Here, we report the identification of somatic mutations in UPF1, a gene that encodes an essential component of the nonsense-mediated RNA decay (NMD) pathway, in 13 of 15 pulmonary IMT samples. The majority of mutations occurred in a specific region of UPF1 and triggered UPF1 alternative splicing. Several mRNA targets of the NMD pathway were upregulated in IMT samples, indicating that the UPF1 mutations led to reduced NMD magnitude. These upregulated NMD targets included NIK mRNA, which encodes a potent activator of NF-κB. In human lung cells, UPF1 depletion increased expression of chemokine-encoding genes in a NIK-dependent manner. Elevated chemokines and IgE class switching events were observed in IMT samples, consistent with NIK upregulation in these tumors. Together, these results support a model in which UPF1 mutations downregulate NMD, leading to NIK-dependent NF-κB induction, which contributes to the immune infiltration that is characteristic of IMTs. The molecular link between the NMD pathway and IMTs has implications for the diagnosis and treatment of these tumors.

1 January 2014 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
ZSZhijun Shen
Zhijun Shen
YWYanming Wu
Yanming Wu
XCXiao Chen
Xiao Chen
XCXinwen Chang
Xinwen Chang
QZQian Zhou
Qian Zhou
KWKai Wang
Kai Wang
Background: 2-methoxyestradiol (2-ME), a natural metabolite of 17β-estradiol, is synthesized by catechol-O-methyltransferase (COMT). The aim of this study was to explore the maternal 2-ME concentration and placental COMT expression in the different trimesters of normal pregnancy and preeclamptic pregnancies, as well as the effects of 2-ME on cell proliferation and migration of HTR-8/SVneo under normoxic (20% O2) and hypoxic (2.5% O2) conditions. Methods: 2-ME levels were examined by ELISA. COMT protein expression was analyzed by Western blot and immunohistochemistry. Cell proliferation and migration were measured by crystal violet assay and transwell system under either normoxia or hypoxia. Results: Maternal 2-ME concentration was elevated with the progression of pregnancy, in contrast, 2-ME was lower in women diagnosed with mild preeclampsia (mPE; 23%) and severe preeclampsia (sPE; 32%) as compared with normotensive full term pregnancies. Meanwhile, preterm controls had lower levels of 2-ME than full term controls. Soluble cytoplasmic COMT (S-COMT), but not membrane-bound COMT (MB-COMT) levels in placentas were increased by 2.5 fold in the full term vs. the first trimester placentas. Furthermore, 2-ME suppressed cell proliferation under 20% O2 but not 2.5% O2, while 2-ME promoted cell migration under 2.5% but not 20% O2in vitro. Conclusion: Considering 2.5% O2 is a state more closely mimicking in vivo condition, these data suggest a decrease in 2-ME levels may inhibit trophoblast cell migration, possibly leading to PE.

12 October 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JHJuyeong Hong
Juyeong Hong
JLJi Hoon Lee
Ji Hoon Lee
ZZZhao Zhang
Zhao Zhang
YWYanming Wu
Yanming Wu
MYMei Yang
Mei Yang
KXKexin Xu
Kexin Xu
The immunosuppressive tumor microenvironment in some cancer types, such as luminal breast cancer, supports tumor growth and limits therapeutic efficacy. Identifying approaches to induce an immunostimulatory environment could help improve cancer treatment. Here, we demonstrate that inhibition of cancer-intrinsic EZH2 promotes antitumor immunity in estrogen receptor α–positive (ERα+) breast cancer. EZH2 is a component of the polycomb-repressive complex 2 (PRC2) complex, which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3). A 53-gene PRC2 activity signature was closely associated with the immune responses of ERα+ breast cancer cells. The stimulatory effects of EZH2 inhibition on immune surveillance required specific activation of type I IFN signaling. Integrative analysis of PRC2-repressed genes and genome-wide H3K27me3 landscape revealed that type I IFN ligands are epigenetically silenced by H3K27me3. Notably, the transcription factor STAT2, but not STAT1, mediated the immunostimulatory functions of type I IFN signaling. Following EZH2 inhibition, STAT2 was recruited to the promoters of IFN-stimulated genes even in the absence of the cytokines, suggesting the formation of an autocrine IFN-STAT2 axis. In patients with luminal breast cancer, high levels of EZH2 and low levels of STAT2 were associated with the worst antitumor immune responses. Collectively, this work paves the way for the development of an effective therapeutic strategy that may reverse immunosuppression in cancer. Significance: Inhibition of EZH2 activates a type I IFN-STAT2 signaling axis and provides a therapeutic strategy to stimulate antitumor immunity and therapy responsiveness in immunologically cold luminal breast cancer.

1 June 2011 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
YZYi-Fan Zhao
Yi-Fan Zhao
CWChong-Ren Wang
Chong-Ren Wang
YWYan-Ming Wu
Yan-Ming Wu
SMSheng-Lin Ma
Sheng-Lin Ma
YJYuan Ji
Yuan Ji
YLYan-Jun Lu
Yan-Jun Lu